Acute pancreatitis (AP) with infectious complications has high mortality because of early-stage immunosuppression. The programmed cell death-1 (PD-1)/ programmed cell death ligand 1 (PD-L1) pathway is an important host immunosuppression mechanism. Soluble PD-L1 (sPD-L1) expression regulates co-inhibitory signals in malignancies or autoimmune disorders; however, its effects in AP are unknown. Here, we evaluated whether serum sPD-L1 is involved in immune dysfunction and assessed its relationship with infectious complications in early AP. Blood samples were obtained from 56 patients with acute pancreatitis and 21 healthy individuals in this prospective study. Serum sPD-L1 levels within 48 h after AP onset were tested by enzyme-linked immunosorbent assays. Relevant immune parameters (human leucocyte antigen-DR, lymphocyte count) and inflammatory markers (C-reactive protein, white blood cell count) were analysed. sPD-L1 was significantly upregulated in patients with early AP, especially those with infectious complications, compared to healthy controls. Significant negative correlations were observed among monocyte HLA-DR expression, lymphocyte count and sPD-L1 levels in AP. Multivariate regression indicated that sPD-L1 was an independent risk factor for infectious complications in AP. The findings suggest that increased sPD-L1 expression appears to be involved in the development of immunosuppression in the early stage of AP and that sPD-L1 might be an early parameter for prediction of infectious complications in patients with AP.
Introduction
Acute pancreatitis (AP), an inflammatory disorder of the pancreas with varying outcomes, commonly presents clinically as acute abdominal pain; approximately 20% patients develop severe forms of AP and have a poor prognosis [1, 2] . Despite persistent efforts and rapid advances in early anti-inflammatory and organ-supportive treatment measures, the mortality rate remains high, and infectious complications are the dominant cause of late mortality [3, 4] . Early immune dysfunction followed by immunosuppression is associated with infectious complications [5] . Immunosuppression occurs in the early phase of AP, leading to susceptibility of the host to infectious complications and then to systemic sepsis in the late stage [6, 7] . Apoptotic cell death is involved in the development of infectious complications during the early stage of AP. Lymphocytes are thought to be critical in mediating apoptosis during impairment of cellular immunity in AP [8, 9] .
Programmed cell death ligand 1 (PD-L1) is one of the ligands of programmed cell death 1 (PD-1, a co-inhibitory molecule) and is expressed by antigen-presenting cells (APCs) and haematopoietic cells. The PD-1/PD-L1 pathway delivers an inhibitory signal to the immune system by limiting T cell activation and proliferation, ultimately resulting in T cell apoptosis, and mediates the evasion of host immune surveillance [10] [11] [12] . Previous studies have indicated that soluble PD-L1 (sPD-L1) is released with matrix metalloproteinases from the surface of PD-L1-expressing cells; thus, sPD-L1 levels may reflect PD-L1 levels. sPD-L1 may be involved in retention of the biological ability to bind the PD-1 receptor and induction of T cell apoptosis [13, 14] . In addition, it was indicated that sPD-L1 induced immunosuppressive activity [15] . sPD-L1 can be detected in the sera of patients with various cancers, autoimmune diseases and infectious diseases [16] [17] [18] [19] [20] , which further suggests that sPD-L1 plays an important role in the disease process by regulating co-inhibitory signals. However, no studies have addressed the effects of sPD-L1 in AP.
Hence, our study aimed to investigate whether sPD-L1 is involved in immunosuppression in the early stage of AP and to determine the association between sPD-L1 and infectious complications in patients with AP.
Materials and methods
Selection of patients and controls. Fifty-six patients diagnosed with AP during March 2014 to December 2015 were recruited from the critical care department or emergency department of Ruijin Hospital. Twenty-one healthy volunteers from the laboratory staff of Ruijin hospital were included as controls. All of the control participants were matched with the patient population in terms of age and sex.
AP diagnosis is most often established by the presence of two of the three following criteria: abdominal pain consistent with the disease, serum amylase or lipase levels greater than three times the upper limit of the normal range, and characteristic findings from abdominal crosssectional imaging [21] . This study included patients who had AP, were more than 18 years old and had been admitted to the critical care or emergency department within 48 h of onset of AP symptoms. Patients were excluded if any of the following criteria were present: suspected malignancy of the pancreas or biliary tree, a medical history of immunodeficiency or receiving immunosuppressive therapy at the time of study, or nonpancreatic infection or sepsis caused by a second disease. All ICU admissions were followed until discharge from or death in the hospital. Both the APACHE II and Ranson scores [22, 23] were recorded. Other baseline characteristics such as age, sex and possible aetiological factors are also presented in Table 1 .
The severity of AP was categorized according to the revised Atlanta classification system as mild, moderately severe (local complication or transient organ dysfunction) or severe (persistent organ dysfunction) [21] . Interventions included surgery, continuous renal replacement therapy or mechanical ventilation. Infected pancreatic necrosis, bacteremia, pneumonia, infected ascites or urosepsis during admission and at 90-day follow-up were considered infectious complications. Infected necrosis was defined as a positive culture of peripancreatic fluid or pancreatic necrosis obtained during the first percutaneous drainage or during the first surgical intervention. Bacteremia was defined as a positive blood culture sample. Pneumonia was defined based on coughing, dyspnoea, chest radiography showing infiltrative abnormalities and reduced arterial blood gas levels with positive sputum culture. Infected ascites was defined as positive bacterial culture for the intraperitoneal fluid or abdominal fluid aspirated during surgery. Urosepsis was defined as dysuria with bacteremia on the same day. For cases where no bacterial evidence was obtained, infectious complications were diagnosed by experienced clinicians on the basis of the clinical symptoms and signs of patients during admission and 90-day followup. All infections were weighted equally; multiple infections in the same patient were considered to be one endpoint.
Ethics statement. The study was conducted in accordance with the Declaration of Helsinki, and the protocol was approved by the Ruijin Hospital Ethics Committee, Shanghai Jiaotong University School of Medicine, China (Reference Number: 201349 released on 05 July 2013). Written informed consent was obtained from all participants or their relatives.
Blood samples. On the day of inclusion in the study, blood samples were collected from AP patients and healthy volunteers. The whole blood samples were collected by peripheral venipuncture or an indwelling central venous, and then samples were transported to the clinical research centre at 4°C within 1 h of collection. The serum samples sPD-L1 levels were measured using a commercially available sandwich ELISA kit (R&D Systems, Minneapolis, MN, USA) according to the manufacturer's instructions. The minimum detectable concentration of sPD-L1 was 0.369-4.52 pg/ml, and the detection range was 25-1600 pg/ml. Samples were measured in duplicate. The intra-assay and interassay coefficients of variation were below 20%.
Statistical analysis. Continuous variables in the data are presented as the mean AE standard deviation (SD) or median with interquartile range (IQR), whereas categorical variables are shown as frequencies and percentages. All variables were tested for normal distribution using the Kolmogorov-Smirnov test. Student's t-test was used to compare the means of continuous variables and the normality of the data distribution; otherwise, the MannWhitney U-test was used. Categorical data were tested using the chi-squared test (or Fisher's exact test, if necessary). Correlations were assessed using the Spearman rank test. Logistic regression analysis was performed to evaluate the relationship between the relevant variables (i.e. inflammatory makers, traditional immune indicators and disease severity assessed by HCT and APACHE II) and infectious complications. Multivariate logistic regression only involved the variables that showed statistical significance in univariate analysis. The ROC curve was used to assess accuracy. Two-sided P < 0.05 was considered statistically significant. All statistical analyses were performed using IBM SPSS Statistics for Windows (version 23.0). Figures were prepared using GraphPad Prism version 6.0 (GraphPad Software, San Diego, CA, USA).
Results

Study population characteristics
The baseline characteristics of our study population, which included 56 patients (men, 62.5%; mean age, 50.13 AE 14.81 years) are presented in Table 1 . Gallstones (46%) were the most common aetiological factor for AP, followed by hypertriglyceridemia (30%), alcohol consumption (13%), and other unknown factors (11%). The median value for the Acute Physiology and Chronic Health Evaluation II (APACHE II) score for AP was 10.5 (IQR, [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] , indicating relatively high severity. According to the revised Atlanta Classification, 3 patients with AP were classified as having mild AP, 24 as moderately severe AP, and 29 as severe AP. Among the patients with AP, 26.8% had infected peripancreatic necrosis, 17.9% had bloodstream infection, 17.9% had pneumonia, 21.4% had infected ascites, and 3.6% had urosepsis. Laboratory results including WBC, HCT, CRP, lymphocyte count, and HLA-DR are also shown in Table 1 .
Increased sPD-L1 levels in AP
The median sPD-L1 concentration was 63.87 and 48.15 pg/ml for patients with AP and healthy controls, respectively. The sPD-L1 expression level significantly differed between healthy controls and patients with AP (P < 0.001; Fig. 1 ). Patients with AP were divided into two groups depending on the presence of infectious complications: infectious complications (IC) (n = 24) and non-infectious complications (non-IC) (n = 32) groups. Patients with infectious complications had higher sPD-L1 levels than patients without such complications (74.62 vs 59.97 pg/ml; P < 0.01; Fig. 1 ), suggesting that sPD-L1 may associated with infectious complications of AP.
Correlation between traditional immune parameters and sPD-L1 in AP
We analysed the correlation between sPD-L1 levels and traditional immune parameters in patients with AP. Spearman rank correlation analysis revealed a significant inverse correlation between sPD-L1 levels and circulating Figure 1 Comparative analysis of soluble PD-L1 levels in patients with acute pancreatitis and healthy controls. Concentrations of sPD L1 in serum samples from AP (filled circles), HC (filled squares), IC (filled triangles) and non-IC (inversed filled triangles) groups were measured by ELISA. bars indicate the median and interquartile range (IQR) values in each group *, P < 0.01. lymphocyte count (r = À0.275, P < 0.05; Fig. 2 ). Additionally, a significant negative correlation was observed between serum sPD-L1 levels and monocyte HLA-DR expression (r = À0.311, P < 0.05; Fig. 2 ).
Association between serum sPD-L1 levels and infectious complications in AP
We further investigated the factors that are correlated with infectious complications in patients with AP using univariate and multivariate logistic regression. Univariate analysis demonstrated that serum sPD-L1 level (P = 0.006), lymphocyte count (P = 0.010) and monocyte HLA-DR expression (P = 0.017) were significantly associated with infectious complications in AP (Table 2) . Multivariate stepwise logistic analysis showed that the independent factors for predicting infectious complications of patients with AP were sPD-L1 (odds ratio, 1.037; 95% confidence interval (CI): 1.005-1.070; P = 0.022) and lymphocyte count (odds ratio, 0.809; 95% CI, 0.664-0.985; P = 0.035; Table 3 ). Receiver operating characteristic (ROC) analyses were performed to examine the performance of these factors as early predictors of infectious complications in patients with AP (Fig. 3) . The area under the curve (AUC) of sPD-L1 and the lymphocyte count were 0.721 (95% CI, 0.586-0.856; P = 0.005) and 0.731 (95% CI, 0.592-0.870; P = 0.003), respectively. The combination of sPD-L1 and lymphocyte count had moderate to high accuracy in predicting infectious complications in patients with AP (AUC, 0.779; 95% CI: 0.659-0.898; P < 0.001; Table 4 ).
Discussion
The development of infectious complications could lead to poor late prognosis in patients with AP [7] ; immunosuppression develops in the early stage and is recognized as a risk factor for infectious complications in AP [6, 24] . In the current study, we observed early pronounced upregulation of sPD-L1 expression in patients with AP, especially those with infectious complications, and significant inverse correlations among circulating lymphocyte count, monocyte HLA-DR expression, and sPD-L1 expression. .......................................................................................................................................................... .....
Furthermore, sPD-L1 was an independent risk factor for early prediction of infectious complications in AP. Serum sPD-L1 levels of patients in the early acute phase of AP, especially those with infectious complications, were higher than those of healthy volunteers. To our knowledge, change in sPD-L1 levels in AP as measured by ELISA has not been reported to date. It has been suggested that sPD-L1 is shed from the surface of activated PD-L1-expressing cells and has the biological ability to bind the PD-1 receptor in vitro [13, 14] . Serum sPD-L1 has been reported to play an important role in various diseases, such as cancer [16, 25] 、infectious disease [19] and sepsis [20] . In the current study, although circulating PD-L1 levels in AP (median 63.87 pg/ml) were lower than those in previous reports of cancer and infectious disease (median 704 pg/ml and 387.5 pg/ml, respectively) [19, 26] , the levels were still significantly different between patients with AP and healthy controls. The mechanism underlying apoptosis in lymphocytes plays an important role in immune dysfunction in AP [9] . A previous study indicated that sPD-L1 could elicit T lymphocyte apoptosis in vitro [14] . Therefore, we inferred that the remarkable increase in sPD-L1 expression led to T lymphocyte apoptosis in AP, and high sPD-L1 levels were involved in the early phase of immunosuppression in AP.
We observed a significant correlation between decreased circulating lymphocyte count and increased sPD-L1 expression. Yoshifumi et al. indicated that the decrease in peripheral lymphocytes in AP was primarily caused by lymphocyte apoptosis [27] . Frigola et al. reported a significant inductive effect of sPD-L1 on T lymphocyte apoptosis in vitro [14] . It is plausible that sPD-L1 may induce lymphocyte apoptosis in vivo, leading to decreased lymphocyte count in AP. In addition, we found a significant negative correlation between decreased monocyte HLA-DR concentration and increased sPD-L1 expression. Decreased monocyte HLA-DR expression indicates immune functional impairment [28] . Thus, increased sPD-L1 expression reflected destruction of the immune function of patients with AP. Such inverse correlations have also been described in patients with squamous cell carcinoma of the head and neck, where CD14+ HLA-DR -/low myeloidderived suppressor cells (MDSCs) express PD-L1 at a higher level than CD14 + HLA-DR +/high cells to mediate suppression of the T cell response [29] . As a feature of myeloid-derived cells, release of sPD-L1 is associated with the amount of PD-L1 expressing cells [14] . Low HLA-DR expression has been suggested to be associated with development of secondary infections and poor outcome in AP [6, 30] . Recently, Drewry et al. demonstrated that monocyte HLA-DR expression may be an accurate predictor of mortality and acquisition of secondary infections in adults with severe sepsis [31] . Consequently, it seems that sPD-L1 is involved in the development of immunosuppression and is associated with infectious complications in AP. However, the specific mechanism underlying the involvement of sPD-L1 in immunosuppression needs further study. We could only assume a correlation between immune dysfunction and increased sPD-L1 expression in this study.
Another finding of our study is that sPD-L1 was independently associated with the development of infectious complications in AP. The immunosuppression phase is characterized by decreased lymphocyte count and monocyte HLA-DR expression [6, 32] . Univariate logistic regression indicated increased sPD-L1 levels, decreased circulating lymphocyte count, and decreased HLA-DR expression by CD14 + monocytes in patients with infectious complications as compared to the levels in patients without such complications, which was in accordance with the phenomenon of immune dysfunction. Multivariate stepwise logistic analysis showed that sPD-L1 levels and lymphocyte count were independently associated with the development of infectious complications in AP. This is consistent with a previous study showing that reduced lymphocyte count within 48 h of AP onset were independently associated with the development of infected pancreatic necrosis [33] . Pronounced downregulation of HLA-DR expression was also seen in patients who had AP with infectious complications. However, the relationship between HLA-DR expression and infectious complications was not sufficiently strong in our study; further large-scale studies are required to confirm this effect. Multivariable scales, such as Ranson and APACHE II, are conventionally used to assess severity in patients with AP. The Ranson scoring system was not incorporated into our logistic analysis because of its weakness in evaluating systemic complications during the mid-late phase of the disease. Multivariate analysis in previous research has shown that the APACHE II score is related to the development of secondary pancreatic infection [34] . Our finding that the APACHE II score was not an independent factor in the multivariate analysis conflicted with this previous research; this difference may be attributed to the limited sample number and the characteristics of participant distribution. Our study population included a large number of cases with AP wherein surgery was required; such patients may be prone to developing infectious complications, which may have influenced the results. Additionally, the currently used scoring systems are not sufficiently accurate for predicting the development of infectious complications. On the basis of our logistic regression analyses, the combination of sPD-L1 and lymphocyte count could help to predict the development of infectious complications with moderate to high accuracy in patients with AP. Furthermore, sPD-L1 measurement by enzyme-linked immunosorbent assay (ELISA) was easy and quick in clinical practice. PD-1/PD-L1 blockade presents a new target for effective immunotherapy for cancer [35] ; our findings may also provide new potential therapeutic targets for treatment of infectious complications in AP based on the aetiological factors.
Further research is, however, required because of some limitations in our study. First, we only measured serum sPD-L1 expression without evaluating expression of PD-L1 on the cell surface. It is difficult to explore roles of the PD-1/PD-L1 pathway in the pathogenesis of AP. Second, our study population comprised patients who were admitted to the intensive care unit (ICU); therefore, our results may not be generalizable to patients with less severe illness. Lastly, our study involved a single centre and included only 56 patients; further multicentre clinical studies with larger cohorts are required to validate our results.
In conclusion, increased sPD-L1 expression appears to be involved in the development of immunosuppression in the early stage of AP. Furthermore, sPD-L1 may be an early independent predictor for infectious complications in patients with AP.
